A $200M valuation, TV commercials, and billboards: A closer (critical) look at how Hims is fast-tracking the modern luxury playbook.
The men’s wellness upstart is (wisely) fast-tracking the DNVB playbook, but we’re worried whether a $200M valuation is justified for a consumer-facing brand that’s only four months into business.
Warby Parker’s Neil Blumenthal articulates modern luxury thinking perfectly in this panel talk.
Warby’s cofounder echos a major point we’ve been making over texts, calls, emails, and dinners with friends and readers for some time now: When thinking about modern luxury today, product alone isn’t enough. It’s the package that really matters.
Neil Blumenthal and Dave Gilboa: “Warby’s next step could be telemedicine, and we want to be a pioneer.”
Having already conquered branding, retail, and product, Warby Parker is eyeing new frontiers as it gears up for international expansion and an inevitable IPO. One big opportunity for growth: telemedicine.
Warby Parker’s new $15M ‘Optical Lab’: Smart offense or reactive defense?
This goes beyond just making lenses in-house, getting sweet tax breaks, and rubbing shoulders with elected officials.
David Kind and the Eyewear Goliath(s).
With Luxottica and Warby Parker both dominating eyewear, David Kind is carving out a high-end moat in a category that’s ultra competitive at the low end.